A federal jury in Boston awarded $88 million on Tuesday to an Alabama man and his wife in the first Covidien hernia mesh case in the country to reach a verdict, and the evidence that carried the day was not what most people expect from a defective device trial.
There was no smoking gun email. No recalled product. No FDA warning letter read aloud to the jury.
What there was, according to the plaintiff’s case, was a change in what animal the collagen came from.
The Switch Nobody Told Surgeons About
Covidien’s Symbotex composite mesh is polyester, which the body does not tolerate well against bowel. To solve that, Covidien coated the mesh in a collagen barrier. The idea is straightforward: the coating keeps bare polyester away from the intestines for long enough that the abdominal lining can regrow over the implant and take over the job.
Everything depends on the coating outlasting that healing window.
Earlier Covidien products used bovine collagen. Symbotex used porcine collagen, a switch from cow to pig. Reuters reported that the plaintiff’s lawyers argued Covidien knew the porcine version would not last as long as the bovine version it replaced, and did not warn surgeons about the difference.
The numbers put in front of the jury were stark. Covidien’s own scientists testified that the barrier begins deteriorating within hours and is essentially gone within about seven days. Sales representatives, meanwhile, were trained to tell surgeons the barrier lasted up to 30 days.
A surgeon working from the 30 day figure believes he has a month of protection. The evidence suggested he had a week.
That gap is the entire case. Not that the mesh was unreasonably dangerous in the abstract, but that the doctor holding it in his hands had been given the wrong number.
What the Jury Awarded
Larry Patterson, 61, received a Symbotex implant during a 2017 hernia repair. He later suffered a bowel obstruction requiring surgery in 2020, including a resection that removed roughly three inches of intestine. His complaint describes significant reconstructive surgery in the aftermath.
After a three week trial before U.S. District Judge Patti B. Saris, the jury found that Covidien failed to provide an adequate warning about the dangers of the mesh. It awarded $77 million to Patterson and $11 million to his wife on her loss of consortium claim.
Patterson’s attorney, Timothy O’Brien, told Reuters the verdict is by far the largest among more than a dozen hernia mesh and transvaginal mesh cases that have gone to trial, and characterized the award as large but proportionate to the damages his clients actually suffered. He told the Minnesota Star Tribune that the injuries had upended the couple’s lives entirely.
Medtronic, Covidien’s parent, said it disagrees with the verdict and will challenge both the liability finding and the size of the award through post-trial motions and, if necessary, appeal. The company maintains that its hernia mesh products have been used safely in millions of patients over two decades.
What the Jury Refused to Do
This part matters more than the headline number, and most of the coverage has buried it.
The jury declined to award punitive damages. It also did not find that Covidien engaged in fraud.
That combination tells you something specific about how twelve people in Boston processed three weeks of evidence. They accepted that surgeons were not told what they needed to know. They did not accept that Covidien set out to deceive anyone. The full $88 million is compensatory, which is to say the jury believed the injuries alone were worth that much before any question of punishment entered the room.
For Medtronic, that is the one genuinely good line on an otherwise brutal verdict sheet. A fraud finding travels badly across a docket of 10,000 cases. A failure to warn finding is narrower and more fact specific.
For plaintiffs, the number itself does the work. An $88 million compensatory award establishes a ceiling nobody had before, and it did not require a jury to find bad intent.
Why This Verdict Moves 10,000 Cases
Medtronic has told investors it faces more than 10,000 hernia mesh claims nationwide. Roughly 2,400 sit in MDL 3029 before Judge Saris in the District of Massachusetts. About 7,450 more are in Massachusetts state court, with several hundred in Minnesota.
By one estimate, roughly a third of all those cases involve the protective coating at issue in Patterson. That is not a fringe theory that happened to win once. It is the central allegation across thousands of files, and it has now survived summary judgment, three weeks of cross examination, and a jury.
Court ordered mediation in the MDL ran out on January 14, 2026 without a global settlement. Covidien elected to try the first case rather than resolve it.
The comparison everyone in this space is making is to C.R. Bard, which lost bellwether trials and then settled tens of thousands of hernia mesh claims in October 2024 in a deal valued at more than $1 billion. Bard read the room after the trial results came in.
Medtronic’s stated plan is to fight this verdict rather than read the room. That is a defensible strategy, and it is not unusual. Companies frequently need a defense verdict of their own before they will negotiate seriously, and additional Symbotex and Parietex Composite bellwethers are already in preparation.
But the arithmetic has changed. Every settlement conversation from this point forward starts with a number that did not exist last week.
For Patients Watching This
A bellwether verdict is a data point, not a payout. It binds the parties to that case and nobody else, the award may be reduced or retried on appeal, and individual outcomes vary enormously with injury severity, surgical history, documentation, and which state’s law applies. Most claims in litigation this size resolve by negotiation at figures far below a headline verdict.
What the verdict does change is timing. Statutes of limitation do not pause while a manufacturer appeals someone else’s case, and claims that are already filed and documented are the ones positioned when a resolution framework eventually appears.
Patients who received Covidien polyester mesh and later required revision or removal surgery, and who have not yet had their claim evaluated, are the ones for whom this week’s news is actually actionable.
Doyle APC handles individual Covidien Parietex and Symbotex hernia mesh injury cases involving revision surgery. Learn more about the Covidien hernia mesh litigation or contact the firm for a free case evaluation.
